Ying Huang’s Post

Our state-of-art cell therapy manufacturing facility in Ghent, Belgium is going to be completed in the near future and contribute to Carvykti supply.

This marks another historic milestone for the Legend Biotech team, as the US FDA approved an expanded label for our CAR-T #CellTherapy. I extend my gratitude to all who contributed to this monumental achievement. #WeAreLegend

I am immensely proud of our team for all the hard work and dedication that went into developing this inaugural ESG report. The Legend team will continue to work with sustainability at the forefront.

Congratulations to our 1,900 team members for the success that has positioned us to help even more patients in 2024.

First CAR T in 2nd line multiple myeloma! I am pleased to share that CHMP of the @European Medicines Agency (EMA) announced a positive opinion for the expansion of our cell therapy, Carvykti, for patients with relapsed and refractory #MultipleMyeloma. We thank SAG-O for their unanimous vote to recommend Carvykti as 2nd line therapy based on the PFS and survival benefit demonstrated in CARTITUDE-4 study. At Legend Biotech, we are steadfast in our commitment to bringing innovative treatment options to the patients who need them most.

Join me in congratulating Legend Biotech’s Chief Medical Officer, Mythili Koneru, M.D., Ph.D., on being named one of the top 17 women leaders in #immunooncology by Immuno-Oncology 360° Her leadership and expertise inspire all of us, and we are proud of her. Read the article here: https://lnkd.in/e9a7Jqa4

We are pleased to announce that Legend Biotech has signed an exclusive, global license agreement with Novartis to advance our investigational CAR T therapy, LB2102, and certain other potential CAR T therapies targeting DLL3. Today marks a significant milestone for all of us at Legend Biotech. This agreement is a true testament to our pipeline of innovative cell therapies and the progress we have made in solid tumor treatment. As we strive to transform the world of oncology and medicine, we will never settle in our commitment to pioneering new therapeutic advances to address unmet medical needs.

It's a privilege to work with a team that's committed to transforming the treatment of multiple myeloma. At ASH 2023 we are gearing up to share two oral presentations and five posters from CARTITUDE development program that highlight our pursuit of innovative treatments for patients with multiple myeloma. I am excited to reconnect with colleagues in the hematology community and demonstrate the progress we are making across the board. Learn more about our efforts: https://lnkd.in/eah9Vdg5 #ASH23 #hematology #oncology

2-Jun Ying Huang, Ph.D. We look forward to sharing exciting updates from the CARTITUDE clinical development program at the @American Society of Clinical Oncology (ASCO) Annual Meeting this weekend. This data affirms how far we’ve come in our pursuit of innovative treatments. For more information about our plans at #ASCO23 visit: https://lnkd.in/eUYGa5iv #LegendBiotech #oncology #celltherapy